Every material Form 8-K NEXGEL, INC. has filed with the SEC since August 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 24, 2026, NexGel began using a shareholder presentation titled "Strategic Review & Proposed Platform Reorganization," filed as Exhibit 99.1. The filing text provided contains no financial figures, and the exhibit's details are not reproduced in the filing text, so the scope of the proposed reorganization cannot be assessed from this filing alone.
Presentation first used on September 24, 2026, and titled "Strategic Review & Proposed Platform Reorganization"
Full presentation attached as Exhibit 99.1, dated September 2026
Information is furnished under Item 7.01 and not deemed "filed" for Section 18 purposes
Filing signed by Brian Kieser, Interim Chief Executive Officer
NexGel terminated CEO Adam R. Levy without Cause effective August 21, 2026, and Levy resigned from the Board. The Board appointed director Brian Kieser as Interim CEO, and formed a Special Committee to review strategic alternatives, liquidity and non-core assets.
Levy's employment was terminated without Cause effective August 21, 2026; he also resigned from the Board and all other company positions.
Brian Kieser, a Board member since May 6, 2026, is Interim CEO. He is also CEO of Sequence LifeScience, which has a strategic partnership with NexGel.
The Special Committee, chaired by Kevin Harris with Steve Glassman, expects to present a strategic and value creation framework to the Board within 30 to 45 days.
The separation agreement with Levy and Kieser's compensation terms have not been finalized; the company will file an 8-K amendment once they are.
NexGel reported second quarter 2026 revenue of $3.69 million and a net loss of $2.87 million, and said its integration and expansion into the surgical channel have moved more slowly than expected. Shareholders did not give sufficient support to the proposed increase in authorized shares and reverse stock split, and the company plans to resubmit them as standalone proposals with completion expected in late September.
Q2 2026 revenue of $3.69 million and net loss of $2.87 million, including $756,554 of BioNX intangible amortization and $273,710 of one-time transaction expenses
BioNX Surgical backlog of approximately $795,000 due to supply chain constraints
Proxy proposals for increased authorized shares and reverse split lacked sufficient support; resolicitation timeline anticipates completion in late September
Investor update call expected on or around September 15, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NEXGEL, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →